Adial Pharmaceuticals Reports Decreased Net Loss and Increased Cash Reserves for Q2 2025

Adial Pharmaceuticals, Inc. reported a net loss of $1.96 million for the three months ended June 30, 2025, a decrease from a loss of $2.46 million in the same period of the previous year. For the six months ended June 30, 2025, the company recorded a net loss of $4.19 million, significantly lower than the $8.93 million loss reported for the first half of 2024. The reduction in losses is attributed to decreased operating expenses, which totaled $1.88 million for the second quarter of 2025, down from $2.29 million in the prior year. The company’s cash and cash equivalents increased to $5.91 million as of June 30, 2025, compared to $3.75 million at the end of 2024.

Adial's operating expenses for the second quarter of 2025 were lower primarily due to a 28% reduction in research and development costs, which fell to $732,000 from $1.01 million year-over-year. General and administrative expenses also decreased by 10% to $1.15 million. The company noted that the decrease in R&D expenses was driven by reduced contract labor and clinical activity. Additionally, the company recognized a milestone payment of $150,000 from its equity method investment in Adovate, LLC, contributing to a more favorable financial position.

In terms of strategic developments, Adial has been focused on advancing its investigational drug candidate, AD04, for the treatment of alcohol use disorder. The company received positive feedback from the FDA regarding its clinical development strategy and is preparing for a Phase 3 clinical trial. Furthermore, Adial has engaged in several financing activities, including a warrant inducement agreement that generated approximately $2.2 million in net proceeds and a best-efforts offering that raised around $3 million in June 2025.

Operationally, Adial's employee headcount has increased as the company continues to expand its capabilities in drug development. The company is actively pursuing additional funding to support its ongoing clinical trials and operational needs, as it anticipates requiring between $8 million to $12 million for future Phase 3 trials. Despite the recent capital raises, Adial's management has expressed concerns about the company's ability to sustain operations without further financing, raising substantial doubt about its ability to continue as a going concern.

Looking ahead, Adial Pharmaceuticals is focused on completing the clinical development of AD04 and obtaining necessary regulatory approvals. The company plans to continue its efforts to secure additional funding through various means, including equity offerings and strategic partnerships. However, the management has acknowledged the challenges in raising capital and the potential impact on its operational plans, emphasizing the need for ongoing financial support to achieve its strategic objectives.